Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q2 2024 · 10-Q
Revenue—
Net Income$9.21M$9.21MN/M vs Q2 2023 EPS Diluted$0.22$0.22N/M vs Q2 2023 Operating Income-$3,135,000N/M Operating Cash Flowderived$2,076,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Free Cash Flowderived$2,076,000N/M ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end